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Atherosclerosis is an inflammatory disease. Autoimmune responses to low-density 
lipoproteins (LDL) contribute to its progression, while immunization with LDL may induce 
atheroprotective or proatherogenic responses. The objective of this study was to develop an 
atheroprotective vaccine by targeting a peptide of the LDL protein constituent apolipoprotein 
B-100 (apoB100) to the nasal mucosa to induce a protective mucosal immune response. 
METHODS AND RESULTS:  
A peptide comprising amino acids 3136-3155 of apoB-100 (p210) was fused to the B subunit 
of cholera toxin (CTB), which binds to a ganglioside on mucosal epithelia. The effect of nasal 
administration of the p210-CTB fusion protein on atherogenesis was compared with that of an 
ovalbumin peptide fused to CTB and with untreated controls. Immunization with p210-CTB 
for 12 weeks caused a 35% reduction in aortic lesion size of Apoe-/- mice. This effect was 
accompanied by induction regulatory T cells that markedly suppressed effector T cells re-
challenged with apoB-100 and increased numbers of IL-10+ CD4+ T cells. Furthermore, a 
peptide-specific antibody response was observed. Atheroprotection was also documented in 
apoe-/- mice lacking functional transforming growth factor-beta receptors on T cells. 
CONCLUSIONS:  
Nasal administration of an apoB100 peptide fused to CTB attenuates atherosclerosis and 




A novel strategy for atheroprotective immunization has been developed. A peptide sequence 
from apolipoprotein B-100 of low-density lipoprotein was fused with the B subunit of cholera 
toxin and used for intranasal immunization of Apoe-/- mice. This induced antigen-specific 
regulatory T cells and led to a 35% reduction of atherosclerosis. 
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INTRODUCTION: 
Preventing the clinical manifestations of atherosclerosis remains a major challenge despite the 
success of current statin therapy (1). Lipid retention and modification in the arterial intima 
elicit a chronic inflammatory process with autoimmune responses and the development of 
atherosclerotic lesions (2). Both adaptive and innate immune mechanisms contribute to this 
process (3-6). While pattern recognition receptors of innate immunity account for cholesterol 
uptake and contribute to activation of macrophages and endothelial cells, antigen-specific T 
cells recognizing low density lipoprotein (LDL) particles in the intima provide strong 
proinflammatory stimuli that accelerate atherogenesis. Accordingly, immunomodulatory 
strategies have shown remarkable effects in animal models of atherosclerosis. 
Antigen-specific immunomodulation by vaccination is an attractive approach to prevent or 
treat chronic inflammatory diseases. By mobilizing protective immune responses in an 
antigen-specific manner, side effects due to hampered host defense against infections are 
avoided. Therefore, antigen-specific suppression of pathologic autoimmunity is of interest in 
chronic inflammatory diseases such as atherosclerosis. Indeed, several studies have 
demonstrated beneficial effects on atherosclerosis in mice and rabbits immunized with LDL, 
beta2-glycoprotein-1b, or heat-shock protein 60/65, and parenteral (7-10) as well as oral (11-
14) immunization reduced atherosclerotic disease in hyperlipidemic animals. However, 
progress has been hampered by limited understanding of the mechanisms through which 
immunization inhibits the disease process. 
Antigen-specific immunoprotection can be achieved through several different mechanisms, 
such as production of protective antibodies, deletion or inactivation (anergy) of pathogenic T 
cell clones, or induction of suppressive cellular immunity mediated by the family of 
regulatory T cells (Treg) (15-16). Although antibodies to LDL components are formed upon 
immunization, their titers or isotypes correlate only partially to the protective effect. Cellular 
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immunity appears also to be targeted but it remains unclear whether it is specific for LDL 
antigens. Finally, several LDL components are bioactive and proinflammatory and may, when 
injected, cause undesirable local or systemic effects. Therefore, immunization with 
immunodominant peptide sequences that have been identified in the protein moiety of LDL, 
apolipoprotein B-100 (apoB-100) should be an attractive alternative to immunization with 
LDL particles (17-18).  
An immunization protocol that facilitates selective targeting of antigen-specific Treg would 
constitute a major step forward in the development of a vaccine against atherosclerosis. The 
type of immune response triggered is largely determined by the route of immunization. 
Subcutaneous antigen administration often leads to inflammatory responses. In contrast, the 
mucosal linings of airways and intestines contain lymphatic tissue that, when exposed to 
antigen, elicits anti-inflammatory, immunosuppressive responses (19). Distinct 
immunological features of the respiratory and intestinal mucosa lead to partly different types 
of protective immunity upon antigen exposure by the nasal or oral route (20). The B subunit 
of cholera toxin (CTB) promotes uptake of antigen via the nasal and oral mucosa and 
induction of protective immunity (21). Therefore, immunization with CTB-antigen conjugates 
has evolved as a promising therapeutic strategy in a variety of autoimmune diseases including 
a first human phase 2 trial in Behcet´s disease (22).  
In this study we present a novel strategy for immunoprotection against atherosclerosis by 
nasal administration of an apoB100 peptide-CTB fusion protein (p210-CTB). This treatment 
significantly reduced atherosclerosis in apoe-/- mice and was associated with induction of 






For a detailed methods description please see Supplemental Material at 
http://atvb.ahajournals.org.  
A recombinant protein, p210-CTB, was made from amino acids 3136-3155 of human apoB-
100 (p210) (17) fused with CTB. This sequence is identical to the corresponding murine 
sequence with the exception of a 2-residue insert at the C-terminal end in the mouse (see 
Online Supplement). As a control, amino acids 323-339 of ovalbumin were fused to CTB 
(OVA-CTB). 8-week-old female apoe-/- mice received a nasal spray with 15 µg (in 15 µL) 
p210-CTB or OVA-CTB twice weekly. Lesions and immune parameters were analyzed 12 
weeks later. In another set of experiments, apoe-/- x CD4dnTGFbRII mice (23) were 
immunized using the same protocol. All experiments were approved by the Stockholm 
regional ethical board. Atherosclerotic lesions were analyzed in cryostat sections of the aortic 
root using a standardized protocol (24). Antibodies to p210 and to mouse LDL particles were 
analyzed by immunometric ELISA (17). Other assays were performed as described in the 
Online Supplement. 
Antigen-specific Treg activity was analyzed in the following way: apoe-/- mice were 
immunized subcutaneously with apoB-100 to generate effector T cells. CD4+ T cells from 
these mice were exposed to antigen and activation recorded as DNA synthesis. CD4+ T cells 
from apoe-/- mice immunized intra-nasally with p210-CTB were added to effector T cell 
preparations and Treg activity was recorded as inhibition of DNA synthesis (see Online 
Supplement). Intracellular staining was performed on CD4+ T cells to characterize cytokine 




Nasal administration of p210-CTB inhibits atherosclerosis  
Nasal immunization with p210-CTB caused a significant 35% reduction in atherosclerotic 
lesion size (p = 0.015; p = 0.039) and fractional lesion area (p = 0.012; p = 0.007) in the aortic 
root as compared with OVA-CTB or untreated controls, respectively (Fig 1A-D and Online 
Supplement, Fig I, please see http://atvb.ahajournals.org). Atherosclerosis was not attenuated 
by administration of OVA-CTB compared with untreated controls indicating an apoB-100 
peptide-specific effect (Fig 1A-D). The composition of the lesions was not significantly 
altered by p210-CTB immunization, as indicated by quantitative immunohistochemical 
analysis of markers for CD4+ T cells, macrophages (CD68), or the inducible surface proteins 
I-Ab (major histocompatibility complex class II protein) and the vascular cell adhesion 
molecule-1 (Supplement, Table 1).  
Nasal administration of p210-CTB does not affect plasma lipids 
Immunization did not significantly affect body weight, serum cholesterol or triglycerides 
(Table 2, Supplement). Plasma lipoprotein profiles were similar in mice immunized with 
p210-CTB or OVA-CTB, respectively (Supplement, Fig II).  
CTB fusion protein immunization increases aortic FoxP3 and IL-10 mRNA levels 
Real-time reverse transcription-PCR analysis of the thoracic aorta of apoe-/- mice showed 
significant increases in FoxP3 and IL-10 mRNA levels in both CTB vaccine groups (p210-
CTB and OVA-CTB) (Figure 1E). No statistically relevant differences in FoxP3 or IL-10 
mRNA were detected when comparing mice that had received p210-CTB or OVA-CTB, 
respectively. Furthermore, numbers of FoxP3+ cells in aortic lesions did not differ between 
the groups ( (Figure III; Supplement).  IL-10 was elevated to the same extent in p210-CTB 
and OVA-CTB groups, pointing to a possible adjuvant effect of CTB. Trends towards 
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increased TGF- and decreased interferon (IFN)- mRNA in vaccinated mice were not 
significant.   
Nasal vaccination induces mucosal and systemic humoral and cellular immune 
responses  
P210-CTB immunization induced significantly elevated titers of IgG antibodies to the p210 
peptide of apoB-100 (Figure 2A). Modestly increased IgG anti-p210 was observed in OVA-
CTB immunized apoe-/- mice. The IgG1/IgG2a ratio of anti-p210 antibodies did not change, 
implying that there was no Th1/Th2 shift in T helper activity to B cell activation (Figure IV + 
V, Supplement). Total IgG levels were not influenced by either treatment (Figure VI, 
Supplement). p210-specific IgM titers did not differ between p210-CTB and OVA-CTB 
treated groups, however, they were significantly elevated compared to untreated animals 
(Figure 2B). Total IgM was not influenced by either treatment (Figure VII, Supplement).  
Sera of immunized mice were tested for antibodies to mouse LDL particles, however, ELISA 
did not show any such titers (data not shown). Therefore, antibodies induced to human p210 
did not recognize intact, endogenous LDL particles in the immunized mice. Apoe-/- mice 
immunized with OVA-CTB showed modestly increased titers to p210 (Fig 2). To rule out the 
possibility of a crossreaction between the OVA peptide and p210, we performed ELISA 
analysis of anti-LDL reactivity in wildtype C57BL/6 mice immunized with OVA-CTB. It 
showed no significant titers to mouse LDL (Fig. XIII, Supplement). 
Analysis of the cellular immune response in the lung, the major organ targeted after nasal 
vaccination, showed a significant decrease in CD4+ T cells expressing IFN-γ (characteristic of 
Th1 cells) and IL-17 (characteristic of Th17 cells), respectively, in mice treated with p210-
CTB (Figure 3 A,B). In contrast, no such change was recorded for IL-4+ CD4+ T cells or for 
FoxP3+ CD4+ T cells (Fig 3 C,D). This indicates a shift of the T helper cell balance in the 
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respiratory mucosa, away from the proinflammatory Th1 and Th17 subtypes after nasal 
immunization with p210-CTB. 
Systemic cellular immune responses were monitored in spleen cell preparations. Nasal 
immunization with p210-CTB significantly increased the proportion of spleen CD4+ T cells 
expressing the anti-inflammatory cytokine IL-10 (Figure 4 A and B). Unlike the situation in 
the lung, no significant differences were detected in the distribution of the remaining CD4+ T 
cell subsets in the spleen, as characterized by intracellular staining for interferon-γ, IL-17, IL-
4 and FoxP3 (Figure VIII, Supplement).  
p210-CTB treatment induces apoB-100-specific Treg activity 
To assess whether functional Treg were induced by immunization, we exposed spleen CD4+ T 
cells from apoe-/- mice immunized subcutaneously with human apoB-100 (effector T cells), to 
CD4+ T cells from mice immunized nasally with either p210-CTB, OVA-CTB, or no antigen 
(Fig. 4C). A marked dose-dependent inhibition of effector T cell proliferation was observed in 
the presence of CD4+ T cells from p210-CTB immunized mice. No such inhibition was 
observed when T cells from OVA-CTB- or non-immunized mice were added. The inhibitory 
effect of T cells from p210-CTB immunized mice was abolished when these cells were 
separated from effector T cells by a membrane, indicating that suppression required cell-cell 
contact (Figure IX, Supplement). Levels of IL-10 and TGF- in culture supernatants did not 
differ between groups (Figure X, Supplement).   
The atheroprotective effect of nasal p210-CTB vaccination is independent of TGF- 
signaling in T cells  
To determine whether the atheroprotective effect of nasal vaccination with p210-CTB 
depended on TGF- signaling in T cells, we immunized apoe-/- mice lacking functional TGF-
 receptors on T cells (Apoe-/- x CD4dnTGFRII mice). Nasal immunization with p210-CTB 
significantly reduced atherosclerotic lesion size by 30% in Apoe-/- x CD4dnTGFRII mice 
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mice, as compared with littermates immunized with OVA-CTB (Fig 5A and Supplement, 
Figure XI). This indicates that TGFR signaling in T cells is not required for the 
atheroprotective effect of nasal p210-CTB vaccination. It also argues against a decisive role 
for FoxP3+ Treg, as these cells are thought to require TGF for their function. IgG but not 
IgM antibodies directed against the apoB100-peptide were significantly elevated in all groups 
of mice immunized with p210-CTB, irrespective of whether signaling via TGF-β was blocked 
during immunization (Figure 5B,C). Analysis of mRNA expression in aortas showed no 
differences in mRNA for, IL-10, TGF- or IFN between p210-CTB- and OVA-CTB-
vaccinated mice (Figure XII, Supplement). Surprisingly, FoxP3 mRNA was elevated in Apoe-
/- x CD4dnTGFRII mice compared to Apoe-/- mice, possibly reflecting the presence of 
immature Treg in the former mice (Figure XII, Supplement and Fig. 1E). Furthermore, 
quantitative analysis of immunohistochemical staining showed no differences in the cellular 
composition of lesions between treatment groups (Table 3, Supplement). 
 
DISCUSSION 
This study presents a novel strategy for induction of atheroprotective immunity involving 
antigen-specific Treg. By nasal administration of a fusion protein between an 
immunodominant peptide of apoB-100 and immunomodulatory CTB, we were able to induce 
an atheroprotective immune response to apoB-100 that involved expansion of antigen-specific 
CD4+ Treg and inhibition of aortic lesion development.  
Induction of antigen-specific Treg has not been described in studies of atheroprotection using 
parenteral or oral routes for LDL immunization. This is also the first study to show that 
mucosal immunization can induce antigen-specific atheroprotective immunity in apoe-/- mice, 
which spontaneously develop atherosclerosis and are therefore already sensitized to plaque 
antigens such as LDL particles at the time of vaccination. This situation is similar to that in 
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humans with pre-existing lesions but differs from that in ldlr-/- mice, which do not develop 
atherosclerosis unless they are fed a high-fat diet.  
 
Mechanism of atheroprotection 
The atheroprotective effect paralleled an induction of Treg suppression of apoB-100-specific 
effector T cells and an increase in IL-10+ CD4+ T cells. Therefore, our data suggest that nasal 
immunization with p210-CTB protects against atherosclerosis by inducing antigen-specific, 
IL-10+ regulatory Tr1 cells. It is unlikely that atheroprotection involved the 
immunosuppressive cytokine TGF- since nasal immunization with p210-CTB reduced 
atherosclerosis also in mice lacking functional TGF- receptor on T cells.  
Antigen-specific as well as antigen-independent effects have been reported in studies of 
Treg(25). Several studies of autoimmune diseases support the regulation model according to 
which Treg suppress conventional effector T cells with the same antigen specificity. Other 
investigators report that Treg exert major effects on antigen-presenting cells in an antigen-
independent manner. Our data clearly show that antigen-specific atheroprotection was 
paralleled by inhibition of apoB100-specific effector T cells by Treg specific for p210 but not 
OVA. These findings support a protective role for autoantigen-specific Tregs in 
atherosclerosis. 
Two major types of Treg induced in the periphery by antigen exposure have been identified: 
FoxP3+ induced Treg (Th3) (25) and Tr1 cells (26). Tr1 cells are FoxP3 negative, secrete IL-
10, and are believed to play an important role when regulatory immunity is induced by nasal 
immunization (27), (28). As atheroprotection was induced by nasal immunization and 
associated with suppressor T cell activity and IL-10 producing CD4+ T cells, our data is 
compatible with Tr1 induction by p210-CTB. CD4+ T cells with antigen-specific suppressor 
activity were derived from spleen, a known reservoir of Tr1 cells(26).  
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Since FoxP3 mRNA was increased in the aorta of nasally immunized mice, it cannot be ruled 
out that FoxP3+ Treg may also contribute to atheroprotection in this model. These cells may 
not only act directly to control proinflammatory effector T cells but also promote the 
activation of Tr1 cells(19). Furthermore, FoxP3+ natural Treg are known to be 
atheroprotective (29). However, these cells are not likely to mediate atheroprotection induced 
by nasal immunization since abrogation of TGF- signaling known to be crucial for the 
function of natural Treg did not extinguish atheroprotection.  Of note, FoxP3+ natural Treg as 
well as Tr1 cells can be detected in mice lacking TGF- signaling in T cells (reviewed in 
(30)). Treg markers were elevated also in OVA-CTB immunized mice, therefore antigenically 
nonspecific effects may have synergized with antigen-specific mechanisms to confer 
protection.  
Adjuvants are components of the vaccine formulation that enhance immunogenicity of the 
antigen, for instance by promoting their uptake by antigen-presenting cells (19, 29) 
Interestingly, two studies documented an atheroprotective effect of complete Freund’s 
adjuvant in hypercholesterolemic ldlr-/- and apoe-/- mice (31-32). In a recent study, 
subcutaneous administration of alum adjuvant was shown to increase antigen uptake and 
activation of cellular immune responses in hypercholesterolemic mice (33).  Our observation 
of a specific antibody response against the apoB-100 peptide and an immunomodulatory 
cytokine profile in aortas of mice immunized with OVA-CTB corroborates such an adjuvant 
effect, further underlining the importance of using optimal immunomodulatory components in 
vaccine preparations.  
Antibodies to the apoB100 peptide sequence were induced by nasal immunization. However, 
they did not cross-react with native mouse LDL particles. Furthermore, antibody titers were 
not correlated with lesion size (data not shown) and no difference in lipoprotein profiles was 
recorded between apoB-100-CTB immunized and OVA-CTB immunized mice. Therefore, 
atheroprotection was likely due to immunomodulation rather than antibody-dependent 
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elimination of LDL particles. When assessing T-cell dependent antibody responses such as 
anti-p210 IgG in hypercholesterolemic mice, it should be kept in mind that apoB100 derived 
peptides are frequently displayed on MHC class II proteins(34) and that ApoE protein 
modulates the function of antigen-presenting cells(35). 
 
Composition of “LDL vaccine” 
Our results confirm and extend previous reports on atheroprotective effects of immunization 
with LDL or its components (7-10, 14, 17, 18). The use of complete LDL particles as 
immunogens is not attractive for clinical vaccination strategies since these particles may 
contain multiple pro-inflammatory and even potentially toxic molecules such as modified 
lipids and endotoxins. Recent studies have identified a set of apoB-100-derived peptides with 
significant atheroprotective effects (17, 18) enabling development of a structurally defined 
vaccine candidate. Among them, specific native peptides were immunogenic in humans and 
mice and correlated with the extent of atherosclerotic disease (36-37). By combining a limited 
number of peptides in the vaccine, it should be possible to overcome MHC restriction, if 
needed. Combining peptide sequences with immunomodulatory components (adjuvants) such 
as CTB is an attractive approach to selectively induce protective immunity while avoiding 
side effects caused by non-peptide components in LDL particles. Unlike LDL, our novel 
vaccine formulation can be easily manufactured in a reproducible way and under Good 
Manufacturing Practice (GMP) conditions. 
The possibility to induce atheroprotective immunity by nasal administration of an LDL 
component is attractive for clinical medicine. Therefore, its effect should be tested also in 
mice with established advanced lesions to mimick the situation when a therapeutic vaccine 
would be applied. Furthermore, the mucosal immune response to apoB100-CTB peptides 
should be studied in other species, and eventually humans, to determine whether it is similar 
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to or different from the one observed in mice. If the results of such studies are encouraging, a 
vaccination approach in patients likely will have to prove efficacy in already sensitized 
individuals such as those with ongoing coronary artery disease or those with high risk for 
future disease.  
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Figure 1:   
Intranasal p210-CTB administered twice weekly for 12 weeks reduced atherosclerotic lesion 
size in the aortic root of female apoe-/- mice. (A) Data from the three groups are shown: black 
circles represent animals from the p210-CTB group, grey circles animals from the OVA-CTB 
group and white circles animals from the control group, respectively. * indicates p<0.05. (B-
D) Representative photomicrographs show oil red O stained aortic root sections from each 
group (50X magnification). (E) Nasal immunization with CTB fusion proteins increased 
FoxP3 and IL-10 mRNA levels in thoracic aorta from apoe-/- mice after 12 weeks of 
treatment. mRNA transcript ratios based on HPRT expression are shown for each gene of 
interest for all three groups. * indicates p<0.05. 
 
Figure 2:  
Nasal immunization induced a systemic humoral immune response in apoe-/- mice. (A) IgG-
anti-p210 titers in mouse plasma; titration curves are shown in the inset. (B) p210-specific 
IgM titers in plasma from the same mice. * indicates p<0.05. 
 
Figure 3: 
Nasal immunization altered T cell subset composition in lung mucosa. Flow cytometric 
analysis of intracellular subset markers, with cytokine-producing CD4+ T cells as percentage 
of total CD4+ T cells for each of the three groups. (A) IFN-γ; (B) IL-17; (C) IL-4; (D) FoxP3. 




Nasal p210-CTB immunization induced IL-10-producing CD4+ T cells and apoB-100-specific 
Treg activity in spleen. A) Flow cytometric analysis of cultured spleen cells stained for 
intracellular IL-10. (B) Representative flow cytometric plots. (C) Splenic effector cells at 2.5 
x 105 cells/well were generated from apoe-/- mice that had been immunized with human 
apoB100. The stimulation index represents the ratio of 3H thymidine uptake upon stimulation 
with human apoB100 (20 µg/mL) relative to unstimulated cells. Proliferation of effector cells 
alone is indicated in the leftmost bar of each group. Addition of purified CD4+ T cells from 
nasally immunized animals is indicated at different ratios to effector cells. * p<0.05. 
 
Figure 5: 
The protective effect of nasal p210-CTB immunization on atherosclerotic lesion size does not 
depend on TGF- signalling in T cells. A) Lesion size in the aortic root of apoe-/- x 
CD4dnTGFRIItg mice immunized with p210-CTB (black dots) or OVA-CTB (grey dots). 
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